Pharma giant Roche has hit the brakes on its gene therapy drug Elevidys—both in commercial sales and clinical trials—after two patients died from acute liver failure. The company is now scrambling to investigate the link between the treatment and these tragic outcomes.

Editor’s Note: This isn’t just another routine drug recall. Elevidys was a promising gene therapy, and sudden, fatal side effects raise serious questions about its safety—and whether regulators missed red flags. For patients and families banking on breakthrough treatments, it’s a gut punch. For the industry, it’s another reminder of how high the stakes are when fast-tracking cutting-edge meds.